In a nutshell This study evaluated the safety and effectiveness of selinexor (Xpovio) in combination with carfilzomib (Kyprolis) and dexamethasone (Decadron) (XKd) in patients with relapsed/refractory (r/r) multiple myeloma (MM) that still responded to carfilzomib. The data showed that weekly administered XKd was highly effective and...
Read More
In a nutshell The study compared outcomes of once-weekly (OW) versus twice-weekly (TW) carfilzomib (Kyprolis) plus dexamethasone (Decadron) in Japanese patients with relapsed/refractory (RR) multiple myeloma (MM). The authors found that the OW dosage improved overall response rate (ORR) compared to TW in such patients. Some background RR-MM...
Read MoreIn a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...
Read More
In a nutshell This paper studied the use of carfilzomib (Kyprolis) in high-risk patients with multiple myeloma. This study concluded that carfilzomib improved survival and response to treatment. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Following treatment, many patients relapse (have a...
Read More
